Bruce joined Alliance Advisors Investor Relations in 2023 through the acquisition of LHA, which he joined in 1997.

Bruce is a seasoned investor relations professional who has worked in the healthcare sector since 1990, primarily in consulting settings. He leads the firm’s global medical practice, having served more than 500 biotechnology, pharmaceutical, medical device, diagnostics and services companies. His clients range from development-stage to members of the S&P 500, Fortune 500 and NASDAQ 100, working in most every disease category and trading on all U.S. and several international stock exchanges.

Bruce has provided counsel to C-suite executives on all aspects of investor relations with a particular focus on high-impact/high-visibility events including M&A transactions, clinical trial readouts, regulatory actions, crisis support, executive transitions and shifts in corporate strategy. He enjoys extensive relationships within the business and financial communities. His clients have raised more than $5 billion via equity and convertible debt issuances, royalty monetization and asset sales, including nearly two dozen IPOs, reverse mergers and de-SPAC transactions.

Bruce has won numerous industry awards and has lectured at NASDAQ, NIRI and Up-Listing events. He holds an MBA from NYU’s Stern School of Business, a BS from the Carlson School of Management and a BA from the University of Minnesota.